Base to Base Biotech

Jim Cornall
  • 0.0 (0)
  • Medicine
  • Weekly

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

  1. 13h ago

    Base to Base biotech podcast 84: 3D printing and secretomes

    This week, we have a conversation with Dylan Yeo, CEO and co-founder of Klona Biotech about 3D printing of regenerative implants, and we chat with Joana Correia, CEO, CSO, and co-founder of Exogenus Therapeutics, about a new consortium leading the way on secretomes. Times: 03:28 Klona Biotech 25:30 Exogenus Therapeutics Klona Biotech Klona is developing the first bioprinting system specifically designed to print regenerative implants for fibrous human tissues. Its bioprinting system integrates in-house developed software, hardware, and material science to produce constructs that replicate the fibrous microarchitecture of structural tissues and the necessary strength and flexibility for their function. Its goal is to create the necessary manufacturing layer to 3D print whole human tissues on demand for grafts and transplants. Exogenus Therapeutics The ExoCordOA consortium recently launched a five-year, €13m project to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis. Led by Exogenus Therapeutics, ExoCordOA brings together 10 organisations with complementary expertise across different disciplines. The consortium will support the development of a new secretome-based medicine for osteoarthritis and help build the foundations for Europe’s leadership in secretome-based therapeutics. A central objective is to advance Exogenus’ lead candidate, EXO-101, towards clinical validation as a potential disease-modifying treatment for osteoarthritis. The programme will support clinical development while also addressing key scientific, manufacturing, quality-control and regulatory challenges that currently limit the clinical translation of extracellular vesicle and secretome therapies. The consortium aims to resolve systemic bottlenecks by helping to develop more standardised approaches, robust analytical and potency assessment methods, and a clearer regulatory pathway for future secretome-based medicines. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 84: 3D printing and secretomes

  2. Nov 6

    Base to Base biotech podcast 83: Different approaches to beating cancer tumours

    Times: 03:22 Ona Therapeutics 24:08 Actuate Therapeutics This week, we have a conversation with Valerie Vanhooren, CEO and co-founder of Ona Therapeutics about first-in-class ADCs for tackling tumours, and Daniel Schmitt, president and CEO of Actuate Therapeutics, about targeting multiple molecular pathways in cancer that are involved in promoting tumour growth. Ona Therapeutics Ona Therapeutics has reached an important milestone in its development, advancing as a clinical-stage company with its lead first-in-class ADC, ONA-255, now progressing through phase 1a clinical development. More than half of the planned patients have already been enrolled in the study. Alongside this, Ona has appointed oncologist and physician Aleix Prat as chief medical officer. Prat has worked closely with the company and played a key role in the identification and validation of the target underlying ONA-255. ONA-255 is a first-in-class ADC designed to target treatment-resistant tumour biology through a novel mechanism, with an initial focus on HR+/HER2-negative advanced breast cancer and gastric cancer. The programme represents an important milestone for Ona following its $86.6m series B financing earlier this year. The company continues to expand its ADC pipeline, with ONA-389 expected to enter the clinic in the second half of 2027 ONA-418 is advancing a dual-linker, dual-payload approach designed to broaden the potential of Ona's ADC portfolio. Actuate Therapeutics Actuate Therapeutics is developing elraglusib, an investigational GSK-3β inhibitor that targets several pathways involved in tumour growth and drug resistance while also modulating anti-tumour immunity. In metastatic pancreatic cancer, randomised phase 2 results published in Nature Medicine showed that adding elraglusib to standard chemotherapy reduced the risk of death by 38% and roughly doubled 12-month survival. Since then, Actuate has secured FDA clearance for a phase 1/2 study of an oral tablet formulation and is working with both the FDA and EMA on a potential registrational study. The company recently shared new preclinical data from its work with the Mayo Clinic and Northwestern University showing synergy with Revolution Medicines' RAS inhibitors zoldonrasib and daraxonrasib, including in chemotherapy-resistant models. Elraglusib has also produced complete responses in a phase 1 trial in relapsed/refractory Ewing sarcoma, a paediatric cancer with no approved targeted therapies. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 83: Different approaches to beating cancer tumours

  3. Oct 30

    Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

    This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart, and with RougeTx CEO Andrew Lightfoot, about developing a treatment for hereditary haemorrhagic telangiectasia (HHT). Times: 03:34 Isomab 25:29 RougeTx Isomab Isomab, a preclinical UK biotech, recently presented safety data at ESC recently that may not sound particularly exciting at first glance, but the implications for cardiovascular drug development could be significant. For decades, the field has been trying to stimulate new blood vessel growth to restore blood flow to the heart, but concerns that this could increase the risk of cancer or damage to the retina have been a major barrier. Isomab’s systematic review of more than 20 years of clinical trial data found no evidence of these long-held safety concerns, potentially removing a significant obstacle to developing an entirely new class of disease-modifying cardiovascular therapies. Isomab believes its approach could open up a new avenue for treating coronary artery disease. The company has a lead drug candidate in ISM-001, which selectively removes VEGF-A165b to restore the natural signalling balance that enables healthy vascularisation in the heart. VEGF-A165b was first identified in 2001 by David Bates, scientific founder of Isomab, and has since been validated in more than 100 publications from more than 80 independent laboratories worldwide. RougeTx RougeTx, launched recently with a $58m Series A financing to advance first-in-class therapies designed to restore vascular integrity by targeting pericyte dysfunction. RougeTx is developing novel therapies for diseases driven by vascular instability, with lead programme RTX-001 advancing towards first-in-human clinical development for hereditary haemorrhagic telangiectasia (HHT), a serious inherited bleeding disorder for which there are currently no approved therapies. RougeTx's periSCOPE platform is being used to identify additional opportunities across diseases associated with vascular instability. The company is built on more than two decades of research into the role of pericytes in maintaining blood vessel integrity. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

  4. Oct 23

    Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

    This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also have a chat with Apeximmune Therapeutics’ CEO and founder Li-Fen Lee, and senior director of biology Kan Lu, about a new breakthrough in shrinking tumours. Times: 03:11 MitoRx Therapeutics 25:06 Apeximmune Therapeutics MitoRx Therapeutics MitoRx Therapeutics is developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity. Its first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat in people with metabolically unhealthy obesity, by restoring mitochondrial health rather than suppressing appetite. Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industry-standard preclinical model of obesity. MTRX31-driven weight loss does not involve lean mass loss, meaning basal metabolic rate is maintained – providing durable, healthy weight loss. The company recently presented new preclinical data at the EASD conference recently.. Apeximmune Therapeutics Apeximmune Therapeutics, Inc. is an IND-stage biotechnology company in South San Francisco focused on developing novel immunotherapies for patients who do not respond to existing immune checkpoint inhibitors. The company applies proprietary computational target discovery to identify mechanistically distinct immune checkpoints with the potential to expand the reach of immuno-oncology. The company recently saw its research published in Nature with a piece entitled “PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity.” The publication validated PLA2G2D as a novel and mechanistically distinct immune checkpoint capable of addressing resistance to anti-PD-1 therapy. The publication represents the convergence of two independent research programmes – one led by Apeximmune, the other by researchers at Erasmus University Medical Center in Rotterdam, the Netherlands – that arrived at the same target using different approaches. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

  5. Oct 16

    Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

    This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour acidity, and Gene Mack, president and CEO of Gain Therapeutics, about developing allosteric therapies, including taking Parkinson’s disease treatments beyond addressing symptoms. Times: 03:03 Gain Therapeutics 25:48 Dyve Biosciences Gain Therapeutics Gain Therapeutics is developing next-generation allosteric therapies. Its lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Also, it has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumours. Its approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its Magellan platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. Dyve Biosciences Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, invented a first-of-its-kind therapy that delivers sodium bicarbonate through the skin to target tumour acidity throughout the body. The therapy is designed to address a key limitation of earlier efforts, which relied on delivering large amounts of buffering agents orally. In preclinical research with Moffitt Cancer Center, DYV800 made tumours substantially less acidic, restored T-cell activity, slowed tumour growth and improved survival. The findings were recently published in Frontiers in Immunology, and the next step is bringing the therapy to patients. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

  6. Oct 9

    Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease

    This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its Parkinson’s disease trial, and have a conversation with Jordi Fàbrega, co-founder and CEO of CONNECTA Therapeutics, and Josep Prous, co-founder and chief scientific officer, about Fragile X syndrome. Times: 03:15 Teitur Trophics 14:03 CONNECTA Therapeutics Teitur Trophics Teitur Trophics recently announced successful results from its phase I clinical trial of its lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The positive results support plans to initiate a phase II trial in PD patients in 2027, which will be designed to explore the therapeutic benefit and disease modifying potential of TT-P34. TT-P34 is a first-in-class therapy that, through a dual mechanism of action, improves both mitochondrial and lysosomal function. Its unique mode of action, targeting a critical pathway that underpins multiple aspects of pathology, means TT-P34 also has potential as a disease-modifying drug for other neurodegenerative conditions including frontotemporal dementia and Huntington’s disease. CONNECTA CONNECTA Therapeutics is a Barcelona-based clinical-stage biotech company developing first-in-class neuroplasticity modulators for central nervous system (CNS) disorders. The company recently announced a €3.1m financing to support the advancement of CTH120, CONNECTA's lead programme for Fragile X syndrome (FXS), including completion of the ongoing phase IIa clinical trial in adult males with FXS, with topline data expected in mid-2027. The financing comes at a key stage for the company as it works to address the underlying neurobiology of FXS, a rare and currently untreatable neurodevelopmental disorder, through its differentiated neuroplasticity modulation platform. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease

  7. Oct 2

    Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis

    This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment. Times: 01:46 Dicot Pharma 17:21 Allegro Allegro Allegro is a Belgium-based biomedical company which recently announced statistically significant improvements in pain and function in a 30-patient study of hydrocelin, a first-in-class nanotechnology injection for knee osteoarthritis (OA). Rather than lubricating the joint like existing injectables such as hyaluronic acid or corticosteroids, hydrocelin uses cross-linked microparticles designed to physically restore the shock-absorbing mechanics of synovial fluid, thereby targeting a proposed root cause of OA rather than just masking symptoms. Separately, Allegro just completed enrolment in a parallel European feasibility trial two months ahead of schedule. Topline safety/tolerability data are expected in H2 2026 and will inform a planned global registrational study. Dicot Pharma Dicot Pharma is developing the first innovation to erectile dysfunction in last 30 years. Virtually nothing has happened since Viagra and Cialis were introduced. The company has recently been given the green light to start its phase IIb trials in the US, and trials are about to start in the EU, too. The drug, LIB-01 has a completely different mode of action, which means a wider group of men can take it. Taking three pills means the drug will work spontaneously for eight weeks, meaning couples do not need to plan anything. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis

  8. Sep 25

    Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?

    This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we chat with Lew Bender, CEO of Intensity Therapeutics, which is pioneering an intratumoral injection therapy primarily for breast cancer that not only kills the cancer cells in the tumour but throughout the body as well, acting as almost a cancer-killing vaccine. Times: 04:22 Intertwined 29:06 Intensity Therapeutics Intensity Therapeutics Intensity is a late-stage clinical biotech company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumour's dense, high-fat, pressurised environment following direct intratumoral injection. Its clinical trials have demonstrated the ability of INT230-6 to kill tumours and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases, even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies: a phase 1/2 dose-escalation study in metastatic cancers including sarcomas, and a phase 2 randomised controlled clinical trial in locally advanced breast cancer in women without undergoing chemotherapy prior to their surgery. Intertwined Evolution has led to species developing in different ways. Hundreds of millions of years of evolution have produced animals that resist diseases humans still struggle to treat. The mechanisms are already there - in their cells, in their DNA. Intertwined Biosciences is using those “blueprints” to decode disease-resistance mechanisms from the world’s most resilient animals and engineer them into human immune cells - powered by the company’s Virtual Immune Cell model. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com

    Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?
See All (84)

About

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production.

Information

  • Creator
    Jim Cornall
  • Years Active
    2025 - 2026
  • Episodes
    84
  • Rating
    Clean
  • Copyright
    © Ayr Coastal Media Ltd 2025
  • Show Website
    Base to Base Biotech

You Might Also Like